Serum neopterin levels in relation to mild and severe COVID-19.
COVID-19
Kynurenine
Neopterin
Prognostic markers
Tryptophan
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
10 Dec 2020
10 Dec 2020
Historique:
received:
30
07
2020
accepted:
27
11
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is rapidly spreading worldwide. There is limited information about prognostic markers that could help clinicians to identify COVID-19 patients with a poor prognosis. Serum levels of the immune activation marker neopterin has shown to be of prognostic value in patients with SARS. The aim of this study was to investigate whether serum neopterin is associated with the severity of COVID-19. We included 34 patients with confirmed COVID-19 between March 3 and March 30, 2020. Fifteen patients had mild disease and did not require hospitalization, whereas 19 patients developed severe COVID-19 requiring intensive care. Concentrations of serum neopterin, tryptophan, and kynurenine were measured at and repeatedly after inclusion. We found a more than two-fold higher mean concentration of neopterin in severely ill patients (mean value 42.0 nmol/L (SD 18.2)) compared to patients with mild symptoms (16.9 nmol/L (SD 11.0)). All of the severe cases had elevated neopterin concentrations (> 9.1 nmol/L) at the initial sampling with values ranging from 17.2 to 86.7 nmol/L. In comparison, 10 of 15 patients with mild disease had neopterin levels above 9.1 nmol/L, with concentrations in the range from 4.9 to 31.6 nmol/L. Neopterin levels gradually decreased during the course of COVID-19, but severe cases maintained elevated levels for a longer period. Moreover, lower levels of tryptophan and higher levels of kynurenine, indicating an increased tryptophan catabolism, were seen in the group with severe cases. In conclusion, we found that serum neopterin levels are associated with the severity of COVID-19. Our findings suggest that neopterin could be used as a prognostic marker, but further studies are needed to elucidate how it can be used in the clinic.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, is rapidly spreading worldwide. There is limited information about prognostic markers that could help clinicians to identify COVID-19 patients with a poor prognosis. Serum levels of the immune activation marker neopterin has shown to be of prognostic value in patients with SARS. The aim of this study was to investigate whether serum neopterin is associated with the severity of COVID-19.
METHODS
METHODS
We included 34 patients with confirmed COVID-19 between March 3 and March 30, 2020. Fifteen patients had mild disease and did not require hospitalization, whereas 19 patients developed severe COVID-19 requiring intensive care. Concentrations of serum neopterin, tryptophan, and kynurenine were measured at and repeatedly after inclusion.
RESULTS
RESULTS
We found a more than two-fold higher mean concentration of neopterin in severely ill patients (mean value 42.0 nmol/L (SD 18.2)) compared to patients with mild symptoms (16.9 nmol/L (SD 11.0)). All of the severe cases had elevated neopterin concentrations (> 9.1 nmol/L) at the initial sampling with values ranging from 17.2 to 86.7 nmol/L. In comparison, 10 of 15 patients with mild disease had neopterin levels above 9.1 nmol/L, with concentrations in the range from 4.9 to 31.6 nmol/L. Neopterin levels gradually decreased during the course of COVID-19, but severe cases maintained elevated levels for a longer period. Moreover, lower levels of tryptophan and higher levels of kynurenine, indicating an increased tryptophan catabolism, were seen in the group with severe cases.
CONCLUSIONS
CONCLUSIONS
In conclusion, we found that serum neopterin levels are associated with the severity of COVID-19. Our findings suggest that neopterin could be used as a prognostic marker, but further studies are needed to elucidate how it can be used in the clinic.
Identifiants
pubmed: 33302893
doi: 10.1186/s12879-020-05671-7
pii: 10.1186/s12879-020-05671-7
pmc: PMC7726600
doi:
Substances chimiques
Biomarkers
0
Kynurenine
343-65-7
Neopterin
670-65-5
Tryptophan
8DUH1N11BX
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
942Subventions
Organisme : ALF agreement
ID : ALFGBG-717531
Organisme : Science for Life Laboratory
ID : KAW 2020.0182
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Infect. 2006 Sep;53(3):152-8
pubmed: 16413058
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Infect Dis. 1993 Sep;17(3):521-2
pubmed: 8218709
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Clin Chim Acta. 2006 Feb;364(1-2):82-90
pubmed: 16139256
Curr Drug Metab. 2002 Apr;3(2):175-87
pubmed: 12003349
Med Microbiol Immunol. 2002 Oct;191(2):115-8
pubmed: 12410351
Clin Chem. 1997 Dec;43(12):2424-6
pubmed: 9439467
Hepatology. 1988 Jul-Aug;8(4):771-4
pubmed: 3134281
J Exp Med. 1984 Jul 1;160(1):310-6
pubmed: 6429267
Kidney Int Suppl. 1994 Nov;47:S8-11
pubmed: 7869677
Clin Chem. 1998 Apr;44(4):858-62
pubmed: 9554499
Proc Natl Acad Sci U S A. 1984 Feb;81(3):908-12
pubmed: 6422465
J Med Virol. 2020 Aug 29;:
pubmed: 32860465
J Acquir Immune Defic Syndr (1988). 1990;3(9):873-6
pubmed: 2166783
Clin Immunol. 2005 Jul;116(1):18-26
pubmed: 15925828